摘要
目的探讨在利妥昔单抗使用的背景下影响弥漫大B细胞淋巴瘤(DLBCL)患者预后的因素。方法回顾性分析113例病理诊断为DLBCL患者的临床及随访资料,利用多因素二元非条件Logistic回归分析可能影响DLBCL患者预后的因素。结果在应用R-CHOP方案(利妥昔单抗、环磷酰胺、羟基柔红霉素、长春新碱和泼尼松龙)治疗的DLBCL患者中,年龄[OlR=1.144(95%CI:1.071,1.221)]、Ann Arbor分期[OlR=4.633(95%CI:1.321,16.254)]、骨髓是否受累[OlR=9.688(95%CI:1.346,69.734)]、血红蛋白分级程度Hb 2级(G2)[OlR=9.492(95%CI:1.269,70.979)]、Hb3级(G3)[OlR=48.456(95%CI:5.926,396.253)]均是影响DLBCL患者预后的危险因素;通过趋势检验发现贫血程度越严重,患者预后越差(χ^2=27.415,P=0.000)。结论在应用R-CHOP方案治疗的DLBCL患者中,患者的年龄、临床分期、骨髓是否浸润、血红蛋白分级程度(Hb2级、Hb3级)对DLBCL患者的预后影响较大,且化疗前贫血程度越严重,患者的预后越差。
Objective To explore the prognostic factors affecting patients with diffuse large B-cell lymphoma(DLBCL)in the context of rituximab,and to improve the quality of patients’prognosis.Medthods A total of 113 cases of pathological diagnosis of clinical information and follow-up data for patients with DLBCL were retrospectively analyzed to find out the factors may affect the prognosis of patients with DLBCL.Results In patients with DLBCL using the R-CHOP regimen,age[O^R=1.144(95%CI:1.071,1.221)],Ann Arbor stage[O^R=4.633(95%CI:1.321,16.254)],bone marrow infiltration[O^R=9.688(95%CI:1.346,69.734)],Hb2 grade(G2100 to 80 g/L)[O^R=9.492(95%CI:1.269,70.979)]and Hb3 grade(G3<80 g/L)[O^R=48.456(95%CI:5.926,396.253)]were the factors affecting the prognosis of patients with DLBCL;through the trend test found that the more severe the degree of anemia,the worse the prognosis of patients(χ^2=27.415,P=0.000).Conclusion In patients with DLBCL using the R-CHOP regimen,the patient’s age,clinical stage,bone marrow infiltration,hemoglobin grade(Hb G2,Hb G3)have great impact on the prognosis of patients with DLBCL.And the more severe the anemia before chemotherapy,the worse the prognosis of patients.
作者
华蕾
王春杰
杨婷婷
刘莉莉
王艳艳
李明霞
王占聚
Lei Hua;Chun-jie Wang;Ting-ting Yang;Li-li Liu;Yan-yan Wang;Ming-xia Li;Zhan-ju Wang(School of Clinical Medicine,Weifang Medical University,Weifang,Shandong 261053,China;Department of Hematology,Affilated Hospital of Weifang Medical University,Weifang,Shandong 261031,China)
出处
《中国现代医学杂志》
CAS
2020年第11期98-102,共5页
China Journal of Modern Medicine
